|
Powered by Cell Signaling Technology |
| Site Information |
|---|
| LHSELGQyPGITFCN SwissProt Entrez-Gene |
| Blast this site against: NCBI SwissProt PDB |
| Site Group ID: 476938 |
| Associated spectra: 1 CST |
| In vivo Characterization | |
|---|---|
| Methods used to characterize site in vivo: | |
| Disease tissue studied: | |
| Relevant cell line - cell type - tissue: | |
| References | |
|---|---|
|
Gu T (2007) CST Curation Set: 3408; Year: 2007; Biosample/Treatment: cell line, Baf3(PLXSN-NEO-FLT3 (D835Y))/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info |
|
|
Gu T (2007) CST Curation Set: 3409; Year: 2007; Biosample/Treatment: cell line, Baf3(PLXSN-NEO-FLT3 (D835Y))/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info |
|
|
Gu T (2005) CST Curation Set: 1059; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info |
|
|
Gu T (2005) CST Curation Set: 1060; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info |